Alectinib versus crizotinib in ALK‐positive advanced non‐small cell lung cancer and comparison of next‐generation TKIs after crizotinib failure: Real‐world evidence - Wang - 2022 - Cancer Medicine - Wiley Online Library
Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Comparative effectiveness from a single-arm trial and real-world data: alectinib versus ceritinib
Changing Treatment Paradigm for ALK-Positive Lung Cancer - ILCN.org (ILCN/WCLC)
Cancers | Free Full-Text | Brigatinib and Alectinib for ALK Rearrangement-Positive Advanced Non-Small Cell Lung Cancer with or without Central Nervous System Metastasis: A Systematic Review and Network Meta-Analysis
Potent treatment options in ALK– and MET-positive disease - memoinOncology
Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan - Masuda - 2019 - Cancer Science - Wiley Online Library
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer☆ - ESMO Open
Progression-free survival by IRC Shown is the Kaplan-Meier curve for... | Download Scientific Diagram
Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer | Semantic Scholar
Kaplan-Meier curve for overall survival after total follow-up of ALK+... | Download Scientific Diagram
Final overall survival analysis from the phase III J-ALEX study of alectinib versus crizotinib in ALK inhibitor-naïve Japanese patients with ALK-positive non-small-cell lung cancer - ScienceDirect
A) Kaplan-Meier curve of progression-free survival (PFS) in the... | Download Scientific Diagram
Kaplan-Meier estimates of progression-free survival (PFS) in the... | Download Scientific Diagram
How the CROWN Study Affects Treatment of Patients With ALK-Positive Metastatic Non–Small Cell Lung Cancer
First-Line PFS - ALECENSA® (alectinib)
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study - ScienceDirect
Cardiac Toxicity of Alectinib in Patients With ALK+ Lung Cancer: Outcomes of Cardio-Oncology Follow-Up | JACC: CardioOncology
Overall Survival Data: Primary & Exploratory 5-Year Landmark Analysis - ALECENSA® (alectinib)
Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer - ScienceDirect
Charu Aggarwal, MD, MPH on Twitter: "Final OS analysis of J-ALEX Alectinib vs Crizotinib ✴️ No significant OS difference BUT ✴️ Majority of patients crossed over to alectinib (~78%) @ALKLungCancer @alk_fusion @ASCO #
